Evidence map›Paper›PMID 31659795›Full record

ArticleJournal of clinical laboratory analysis2020

Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease.

Heping Zhao, Ping Zhu, Tao Han, Qing Ye, Cuiping Xu, Lina Wu, Fang Liu, Weili Yin, Zhiyong Li, Ying Guo

Abstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Heping ZhaoThe Third Central Clinical College of Tianjin Medical University, Tianjin, China.ORCID https://orcid.org/0000-0002-9177-5519
Ping ZhuThe Third Central Clinical College of Tianjin Medical University, Tianjin, China.
Tao HanThe Third Central Clinical College of Tianjin Medical University, Tianjin, China.
Qing YeDepartment of Hepatology and Gastroenterology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Artificial Cell, Tianjin Institute of Hepatobiliary Disease, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Third Central Hospital Affiliated to Nankai University, Tianjin, China.
Cuiping XuDepartment of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan, China.
Lina WuDepartment of Pathology, The First Hospital of Shanxi Medical University, Taiyuan, China.
Fang LiuDepartment of Hepatology and Gastroenterology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Artificial Cell, Tianjin Institute of Hepatobiliary Disease, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Third Central Hospital Affiliated to Nankai University, Tianjin, China.
Weili YinDepartment of Hepatology and Gastroenterology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Artificial Cell, Tianjin Institute of Hepatobiliary Disease, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin Third Central Hospital Affiliated to Nankai University, Tianjin, China.
Zhiyong LiSuzhou Erye Pharmaceutical Corporation, Suzhou, China.
Ying GuoDepartment of Hepatology, Taiyuan City Third People's Hospital, Taiyuan, China.

Funding

the 2017 National 13th 5-Year Plan for Hepatitis Research 2017ZX10203201-007the National Natural Science Foundation of China 81870429
6 · The paper itself

Abstract

objectiveTo determine the clinical and liver stiffness characteristics of a cohort of Chinese patients with Hepatocellular carcinoma in different stages of Barcelona clinic liver cancer.

methodsDetails of 1180 patients with Hepatocellular carcinoma referred from October 2014 to November 2017 were collected retrospectively. Demographic data, etiology, clinical, and biochemical details were retrospectively analyzed. The changes of liver stiffness in different etiologies and different stages of Barcelona clinic liver cancer were especially analyzed.

resultsThe onset age was 60.33 ± 9.11 (range 24-84) years, 9 cases were ≤40 years, 572 cases were 41-60 years, males accounted for 83.92%, females accounted for 16.08%; 599 cases were ≥61 years, males accounted for 78.25%, females accounted for 21.75%. Compared with males, the proportion of females ≥61 is higher than that of men. Majority (n = 787; 66.69%) had HBV infection; second commonest cause was HCV infection (n = 217; 18.39%). More patients with HBV infection were 41-60 years (69.06%) and were younger than HCV patients. There was no statistical difference in etiology, age, gender, and distribution of diabetes mellitus among different Barcelona clinic liver cancer stages (P > .05). The overall Hepatocellular carcinoma (HCC) was found to be positively correlated with alkaline phosphatase, γ-glutamyltransferase, and alpha-fetoprotein and liver stiffness measurement values from stage A to stage D (P < .05). ANOVA analysis showed that the overall liver stiffness measurement among the four BCLC stages was found to be statistically significant different in HBV-infected and HCV-infected HCC patients.

conclusionMajority (99.24%) were patients aged >40 years old. Male is a high incidence population. In etiological analysis, HBV dominates HCC occurrence, HBV-, HCV-, and alcohol-associated HCC have distinct clinical and biochemical characteristics, necessitating different screening policies to optimize HCC surveillance and management.

Indexed as

AdultAgedAged, 80 and overAge DistributionAge of OnsetCarcinoma, HepatocellularElasticity Imaging TechniquesFemaleHepatitis BHepatitis CHumansLiver Diseases, AlcoholicLiver NeoplasmsMaleMiddle AgedSex Distributionalcoholic liver diseasealpha-fetoproteinhepatocellular carcinomaliver stiffness measurementviral hepatitis

Identifiers

PMID31659795
PMCPMC7031605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.